James MacKay1,2, Joshua Kaggie1, Graham Treece3, Stephen McDonnell4, and Wasim Khan4
1Department of Radiology, University of Cambridge, Cambridge, United Kingdom, 2Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 3Department of Engineering, University of Cambridge, Cambridge, United Kingdom, 4Department of Surgery, University of Cambridge, Cambridge, United Kingdom
Synopsis
- Conventional MRI outcome measures for cartilage in knee osteoarthritis (OA) clinical studies lack responsiveness and require time-consuming manual analysis.
- Here we validate and clinically implement a semiautomatic surface-based approach termed 3D Cartilage Surface Mapping (3D-CaSM) which overcomes these issues.
- Validation data demonstrate comparable bias, precision, repeatability and reproducibility to expert manual segmentation (current standard) but with >10 fold reduction in analysis time.
- Clinical data indicate improved sensitivity to change in one observational and two interventional (exercise, knee joint distraction) studies.
INTRODUCTION
Traditional quantitative analysis of cartilage with
MRI requires time consuming manual segmentation and averages measurements
(e.g., thickness) across regions of interest (ROIs) which may reduce
responsiveness1.METHODS
The
described work consists of a validation study in cadavers (referred to as the
validation study) and three in-vivo studies demonstrating the clinical
application of this method (referred to as the clinical studies).
The
validation study compared cartilage thickness measurements performed on
embalmed cadaveric knees (n = 4) between MRI and the reference method of high
resolution peripheral quantitative computed tomography (HRpQCT). The first clinical
study assessed the inter-observer reproducibility and test-retest repeatability
of 3D-CaSM and sensitivity to change over six months participants (n = 14) with
knee osteoarthritis (OA) and 6 age-matched healthy volunteers. Subsequent clinical
studies explored the utility of 3D-CaSM for (1) assessing changes in cartilage
composition (T2, T1rho) in response to exercise in 19 healthy knees and (2)
assessing changes in cartilage thickness in response to knee joint distraction
(KJD) treatment in 20 patients with knee OA.
MRI cartilage thickness measurements were
performed using 3D spoiled gradient recalled echo (SPGR) sequences with fat
suppression; MRI cartilage compositional measurements were performed using T1rho/T2 magnetization prepared pseudo-steady-state
3D fast spin echo (FSE) sequences2. Typical
sequence parameters are provided in Figure 1.
The initial 3D-CaSM analysis process is
summarized in Figure 2a. This
results in approximately 6000 thickness measurements for a single knee, together
with accurately located inner and outer cartilage surfaces. These surfaces can
then be imported into compositional maps following appropriate image
registration (Figure 2b) to generate a corresponding set of compositional
measurements. Intra-individual and inter-individual spatially corresponded
analysis is facilitated by surface-to-surface registration to a canonical
(‘average’) surface using a combined similarity/thin plate spline algorithm.
All analyses are performed using freely available software; Stradview (http://mi.eng.cam.ac.uk/Main/StradView/)
for 3D-CaSM and wxRegSurf (http://mi.eng.cam.ac.uk/~ahg/wxRegSurf/)
for surface-to-surface registration.
For the validation study, for each
cadaveric knee a set of corresponding HRpQCT thickness values (resolution
0.08mm isotropic) from disarticulated knees was obtained and compared with
3D-CaSM and expert manual segmentation of the MRI data using Bland-Altman
analysis.
For the clinical studies, Bland-Altman analysis and
root-mean-square coefficients of variation (RMS-CVs) were used for assessment
of test-retest repeatability and inter-observer reproducibility. Responsiveness
to change was assessed at the individual level via calculation of the
percentage of each cartilage surface affected by areas of significant change
(%SC), defined using thresholds based on area and smallest detectable
difference (SDD), and at the group level using statistical parametric mapping
(SPM).RESULTS
3D-CaSM reduces analysis time for a single
knee by >10 fold compared to conventional manual segmentation (15 minutes vs
3 hours). Agreement for cartilage thickness measurement with gold-standard
HRpQCT was good (mean bias [95% limits of agreement] = 0.06 [-0.43,0.56] mm)
and similar to expert manual segmentation (-0.13 [-0.64,0.38] mm).
Inter-observer RMSCVs were similar for 3D-CaSM and manual
segmentation and test-retest repeatability RMSCVs were <10% in all cases (Figure
3).
In the observational clinical study, the number of
participants demonstrating significant changes in cartilage thickness and/or
composition at 6 months was 13/14 with 3D-CaSM vs 1/14 using standard methods.
Use in interventional studies has allowed identification of focal regions of
statistically significant change in cartilage in response to exercise (Figure
4) and following knee joint distraction not detectable by standard methods
(Figure 5).CONCLUSION
3D-CaSM is a valid tool to assess changes
in cartilage morphology and composition over durations relevant to both observational
and interventional clinical studies in OA. Bias, precision, test-retest repeatability and inter-observer
reproducibility are comparable to current gold-standard methods. Improved responsiveness of 3D-CaSM could permit smaller, shorter
duration clinical trials. Work is ongoing to assess association with
symptomatic progression in two large cohort studies (APPROACH &
PROGRESS-OA)3,4.Acknowledgements
No acknowledgement found.References
- Jørgensen DR,
Lillholm M, Genant HK, Dam EB: On Subregional Analysis of Cartilage Loss from
Knee MRI. Cartilage 2013; 4:121–130.
- Chen W, Takahashi A, Han E: 3D Quantitative Imaging of T1rho and T2. In Proc
Intl Soc Mag Reson Med. Volume 19. Montreal; 2011:231.
- Helvoort EM van, Spil WE van, Jansen MP, et al.: Cohort profile: The
Applied Public-Private Research enabling OsteoArthritis Clinical Headway
(IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate
and predict phenotypes of osteoarthritis using clinical, imaging and
biochemical markers. BMJ Open 2020; 10:e035101.
- Biomarkers
Consortium - PROGRESS OA: Clinical Evaluation and Qualification of
Osteoarthritis Biomarkers | FNIH [https://fnih.org/what-we-do/biomarkers-consortium/programs/progress-oa]